Projects per year
I have two main areas of research interests: the study of leishmaniasis and drug delivery. My research on leishmaniasis has been involved in understanding the underlying immunological mechansims involved in the control of the disease, the mechananism responible for drug resistance, and development of novel vaccine fomulations to control the infection. I work on L. donovani, L. major and L. mexicana and we have recently started using luciferase-expressing parasites to track the infection. My drug delivery studies have focused on using non-ionic surfactant vesicles (NIV) to improve drug delivery by the intravenous or pulmonary routes. We are currently involved in commercialising NIV for the pulmonary delivery ('Inhalosomes') through the spin-out comany 'Inhalosome-C Ltd', which is involved in developing a cisplatin product for the treatment of lung cancer.
B10 Fo luc cells imaged using the IVIS® system
Cells were treated with an anticancer drug (columns 3-10) - with the highest concentration in colum 3 and the lowest in column 10. Column 2 shows the results for the control cells and column 11 shows the results for the negative control. This type of assay is used for screening anticancer compounds.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
- drug delivery
- anticancer treatment
- 1 Similar Profiles
Dive into details
Select a country/territory to view shared publications and projects
Submitted grant proposal to skills development Scotlands regional and national partner fund for enhancing professional learning in STEM
Sorensen, A., McLeod, D., Cunningham, M. R., Geddes, K. & Carter, K.
Project: Non-funded project
Immunisation with transgenic L. tarentolae expressing gamma glutamyl cysteine synthetase from pathogenic Leishmania species protected against L. major and L. donovani infection in a murine modelTopuz Ata, D., Hussain, M., Jones, M., Best, J., Wiese, M. & Carter, K. C., 17 May 2023, In: Microorganisms. 11, 5, 17 p., 1322.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile1 Downloads (Pure)
Selective anti-Leishmanial Strathclyde minor groove binders using an N-oxide tail group modificationPerieteanu, M. C., McGee, L. M. C., Shaw, C. D., MacMillan, D. S., Khalaf, A. I., Gillingwater, K., Beveridge, R., Carter, K. C., Suckling, C. J. & Scott, F. J., 7 Oct 2022, In: International Journal of Molecular Sciences. 23, 19, 16 p., 11912.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile7 Downloads (Pure)
Supplementary data for: "Genomic and metabolomic polymorphism among experimentally selected paromomycin-resistant Leishmania donovani strains"
Carter, K. (Creator), University of Strathclyde, Oct 2019
- 1 Key-note speaker and plenary lectures at conferences
4th Worldleish Congress on Leishmaniasis 2009 in Lucknow, India
Katharine Carter (Keynote/plenary speaker)2009
Activity: Participating in or organising an event types › Key-note speaker and plenary lectures at conferences
Economic benefit and competitive advantage from commercial adoption of an innovative non-invasive delivery method for drugs and vaccines
Katharine Carter (Participant), Valerie Ferro (Participant), Alexander Mullen (Participant) & James Alexander (Participant)
Impact: Impact - for External Portal › Economic and commerce, Health and welfare - new products, guidelines and servicesFile